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Abstract
Background: The identification of the HLA class II, insulin (INS), CTLA-4 and PTPN22 genes as
determinants of type 1 diabetes (T1D) susceptibility indicates that fine tuning of the immune system
is centrally involved in disease development. Some genes have been shown to affect several
immune-mediated diseases. Therefore, we tested the hypothesis that alleles of susceptibility genes
previously associated with other immune-mediated diseases might perturb immune homeostasis,
and hence also associate with predisposition to T1D.
Methods: We resequenced and genotyped tag single nucleotide polymorphisms (SNPs) from two
genes, CRP and FCER1B, and genotyped 27 disease-associated polymorphisms from thirteen gene
regions, namely FCRL3, CFH, SLC9A3R1, PADI4, RUNX1, SPINK5, IL1RN, IL1RA, CARD15, IBD5-locus
(including SLC22A4), LAG3, ADAM33 and NFKB1. These genes have been associated previously with
susceptibility to a range of immune-mediated diseases including rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), Graves' disease (GD), psoriasis, psoriatic arthritis (PA), atopy, asthma,
Crohn disease and multiple sclerosis (MS). Our T1D collections are divided into three sample
subsets, consisting of set 1 families (up to 754 families), set 2 families (up to 743 families), and a
case-control collection (ranging from 1,500 to 4,400 cases and 1,500 to 4,600 controls). Each SNP
was genotyped in one or more of these subsets. Our study typically had approximately 80%
statistical power for a minor allele frequency (MAF) >5% and odds ratios (OR) of 1.5 with the type
1 error rate, α = 0.05.
Results: We found no evidence of association with T1D at most of the loci studied 0.02 <P < 1.0.
Only a SNP in ADAM33, rs2787094, was any evidence of association obtained, P = 0.0004 in set 1
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4,610 controls, P = 0.57 (OR = 1.02).
Conclusion: Polymorphisms in a variety of genes previously associated with immune-mediated
disease susceptibility and/or having effects on gene function and the immune system, are unlikely
to be affecting T1D susceptibility in a major way, even though some of the genes tested encode
proteins of immune pathways that are believed to be central to the development of T1D. We
cannot, however, rule out effect sizes smaller than OR 1.5.
Background
The four susceptibility loci identified so far in T1D, the
HLA class II gene complex [1], INS [2], CTLA4 [3] and
PTPN22 [4,5] indicate that the regulation of T cell devel-
opment, activation, expansion and homeostasis is a cen-
tral component of disease development. A fifth locus, the
IL2R2/CD25 region [6] awaits independent replication
and fine mapping of the aetiological variant. With the
exception of INS [7], these genes contain polymorphisms
that are associated with susceptibility to other immune-
mediated diseases.
Therefore, we hypothesised that further susceptibility var-
iants for T1D may reside in genes previously associated
with other immune-mediated diseases, as prior evidence
suggests the presence of shared disease susceptibility
genes. For example, in families with T1D, other immune-
mediated diseases, such as RA and autoimmune thyroid
disease (AITD), occur more frequently than expected by
chance, indicative of a partly shared genetic basis [7]. This
model has gained significant support recently with the
association of the Arg620Trp non-synonymous SNP in
the PTPN22 gene, encoding the lymphoid specific phos-
phatase, LYP; not only with T1D [4] but also with GD, RA
and SLE [5,8,9]. Likewise CTLA4 has been associated with
T1D, AITD, RA and SLE [3,10].
Furthermore, as susceptibility to T1D and other autoim-
mune diseases is probably directly related to the homeo-
static, regulatory state of the immune system, it is possible
that variants in immune response genes influence suscep-
tibility to T1D via alteration of networks of immune regu-
lation. For example, the CARD15 gene product, NOD2,
influences the development of the adaptive immune
response [11,12] and functional variants of the gene pre-
dispose to the inflammatory bowel disease (IBD), Crohn
disease (Table 1). Both the Th1 and mucosal immune sys-
tem are thought to be important in T1D aetiology [13].
The aim of this study was to determine whether previously
associated polymorphisms of immune-mediated disease
also predispose to T1D. We genotyped a total of 41 poly-
morphisms, including three microsatellite markers, from
16 genes, shown in Table 1, in large T1D collections. For
two genes C-reactive protein (CRP), a marker for inflamma-
tion and associated with susceptibility to SLE [14,15], and
FCER1B, high-affinity receptor for immunoglobulin E
(IgE) (MS4A2), located in the putative T1D locus IDDM4,
and associated with atopic illness [16,17], we also carried
out a re-sequencing effort, to gain a more comprehensive
profile of allelic variation of the genes and their potential
association with T1D. Our sample sizes had good statisti-
cal power for ORs greater than 1.5 (Additional File 1)
[18].
Methods
Subjects
T1D families were white European or of white European
descent, with two parents and at least one affected child
comprising DNA samples from up to 476 multiplex Dia-
betes UK Warren 1families [19], 278 multiplex HBDI fam-
ilies [20], 250 simplex Northern Ireland families [21], 260
simplex Norwegian families and 233 simplex Romanian
families with inclusion criteria as reported in Vella et al.
[22]. The T1D cases [23]and the 1958 BBC controls [24]
have been described previously [5]. All DNA samples were
collected after approval from the relevant research ethics
committees and written informed consent was obtained
from the participants. This project has run over a number
of years during which samples of cases were still being col-
lected. Consequently, owing to availability of DNA, poly-
morphisms were genotyped either in "set 1" families (n =
754 UK and USA multiplex families), "set 2" families (n =
743 Norwegian, Romanian and Northern Irish simplex
families) and/or a British case-control collection consist-
ing of between approximately 1,500 and 4,400 cases and
1,500 and 4,600 controls.
SNP identification and genotyping
CRP (EMBL Accession number AL445528) and FCER1B
(AP001181) were annotated locally, importing Ensembl
information into a temporary ACeDB database as
described previously [25]. After confirmation of gene
structures by BLAST analysis, these were re-extracted in
GFF format and submitted to T1Dbase [26].
Direct sequencing of nested PCR products from 32 T1D
individuals was carried out for all exons of CRP and 3 kb
5' and 3' of the gene, using Applied Biosystems 3700 cap-
illary sequencer. Polymorphisms were identified using thePage 2 of 12
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Gene (locus link id) Gene Function Polymorphisms MAF Reference and previous 
association
CRP 1q21-q23 (1401) Activates the classical 
pathway of complement. 
SNP2 alters basal levels of 
CRP. SNP4 has been 
associated with SLE and 
antinuclear autoantibody 
production. A polymorphic 
GT repeat in CRP has been 
associated with SLE.
SNP2 (rs1800947)
SNP4 (rs1205)
Microsatellite 
(ss28514831)
0.07 & 0.33 respectively, 
Caucasian parental. GT16 & 
GT21, 0.62 and 0.24, 
respectively, Caucasian 
controls.
SLE: Microsatellite P = 
0.007, SNP4 P = 0.0008; 
586 families [14].
Microsatellite [15].
FCRL3 1q21-q22 (115352) FCRL3, a member of the Fc 
receptor-like family, 
polymorphism alters the 
binding affinity of nuclear 
factor κB and regulates 
FCRL3 expression. 
Associated with RA, SLE 
and autoimmune thyroid 
disease (GD and HT)
Fcrl3_3 (rs7528684) 0.37 Japanese controls RA: P = 8.5 × 10-7, OR = 
2.15 (95% CI = 1.58–2.93) 
830 cases and 658 
controls. SLE: P = 0.0017, 
OR = 1.49 (95% CI = 1.16–
1.92) 564 cases. GD: P = 
7.4 × 10-5, OR = 1.79 (95% 
CI = 1.34–2.39) 351 cases. 
HT: P = 0.022, OR = 1.62 
(95% CI = 1.07–2.47) 158 
cases [43].
CFH 1q32 (3075) Complement factor H, a 
key regulator of the 
complement system of 
innate immunity, binds 
heparin and CRP
His402Tyr (rs1061170) 0.41 controls, white, not of 
Hispanic origin
Age-related macular 
degeneration: (nominal P = 
<10-7) 96 cases and 50 
controls [44].
PAD14 1q36.13 (23569) Peptidylarginine deiminases 
role in granulocyte & 
macrophage development, 
leading to inflammation and 
immune response, 
associated with RA.
PADI4-94 (rs2240340) 0.37 Japanese controls RA: P = 8 × 10-6, OR = 1.97 
(95% CI = 1.44–2.69) 830 
cases and 736 controls 
[45].
IL1RN & IL1A 2q14 (3557 & 
3552)
Cytokines involved in the 
inflammatory response, 
polymorphisms confer 
susceptibility to RA and 
Ankylosing spondylitis.
IL1RN+2017 (rs2419598)
IL1A-889 (rs1800587)
0.22 & 0.27, respectively, 
Caucasian controls
RA: P = 0.008; 406 Dutch 
cases and 245 controls 
[46].
Ankylosing spondylitis: P = 
0.025; 227 British families, 
317 parent-case trios and 
200 controls [47].
NFKB1 4q24 (4790) NFκB is a transcription 
regulator that is activated 
by various intra- and extra-
cellular stimuli such as 
cytokines, oxidant-free 
radicals, ultraviolet 
irradiation, and bacterial or 
viral products. 
Inappropriate activation of 
NFκB has been associated 
with a number of 
inflammatory diseases
(CA) dinucleotide repeat 
microsatellite
Allele 8, A10 & A14, 0.19, 
0.02 and 0.28 respectively, 
UK controls
T1D: A10: P = 0.000001, 
OR = 9.4; 434 cases, 222 
controls [36]. T1D: no 
association; 236 Danish 
families [37].Page 3 of 12
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organic cation transporter 
and plasma integral 
membrane protein 
containing eleven putative 
transmembrane domains as 
well as a nucleotide-binding 
site motif. Polymorphisms 
confer susceptibility to RA.
SLC22A4:F1 (rs2073838)
SLC22A4:F2 (rs3792876)
0.31 & 0.32 respectively, 
Japanese controls
RA: P = 0.000034, OR = 
1.98 (95% CI = 1.43–2.75) 
830 cases and 658 controls 
[48].
CD: P = 0.001, OR = 2.1 
(95% CI = 1.31–3.39) 203 
cases and 200 controls 
[49].
IBD5 locus 5q31 (50941) Confers susceptibility to 
Crohn disease.
IGR2198 (rs11739135) 0.36 Canadian parental. CD: P = 0.000048; 256 
trios [50].
SPINK5 5q32 (11005) Encodes a 15 domain 
serine proteinase inhibitor 
(LEKTI) involved in anti-
inflammatory and/or 
antimicrobial protection of 
mucous epithelial, 
polymorphisms associated 
with atopy, Netherton 
disease.
316G>A (ss28514851)
1103A>G (rs2303064)
1156G>A (rs2303063)
1258G>A (rs2303067)
2475G>T (rs2303070)
2915A>G (ss28514856)
0.03, 0.50, 0.13, 0.48, 0.08 
& 0.04, respectively, UK 
controls
Atopy, Netherton disease: 
(rs2303064): P = 0.008, 
(rs2303067): P = 0.002; 148 
families [51].
Asthma (rs2303067): P = 
0.04, OR = 1.77 (95% CI = 
1.02–3.06) 1161 children. 
Asthma and atopy: P = 
0.007, OR = 4.56 (95% CI 
= 1.37–15.12) 37 German 
cases and 415 controls 
[52].
FCER1B 11q13 (2206) Encodes the beta subunit 
of the high affinity IgE 
receptor, a member of the 
membrane-spanning 4A 
gene family, and displays 
unique expression patterns 
among hematopoietic cells 
and nonlymphoid tissues. 
Responsible for initiating 
the allergic response, 
associated with atopy and 
atopic asthma.
Gly237Glu (rs569108) 0.06 Japanese controls Atopy: two-point lod score 
9.35 [17].
Childhood asthma 
(rs569108): P = <0.002, OR 
= 3; 200 Japanese cases and 
100 controls [16].
LAG3 12p13.32 (3902) Lymphocyte-activation 
protein 3 belongs to Ig 
superfamily and contains 4 
extracellular Ig-like 
domains.
Thr455Ile (rs870849) N/A MS: P = 0.005; 576 cases 
and 662 controls [53].
CARD15 16q12 (64127) Intracellular sensors of 
bacterial peptidoglycan 
These SNPs encode amino 
acid changes located in or 
near the leucine-rich 
repeat region, which is 
involved in peptidoglycan 
binding, conferring an 
increased risk of Crohn 
disease, PA and Blau 
syndrome.
SNP8 (rs2066844)
SNP12 (rs2066845)
SNP13 (ss28514842)
0.04, 0.01 & 0.02, 
respectively, Caucasian 
controls
CD (SNP13): P = 6 × 10-6; 
235 families [54].
P = 0.0046; 416 
families[55].
PA: P = 0.0027, OR = 3.5 
(95% CI = 1.51–7.01) [56].
Blau Syndrome [57].
SLC9A3R1 17q25 (9368) Immune synapse formation 
in T cells, polymorphism 
associated with psoriasis.
SLC9A3R1 (rs734232) 0.42 European controls Psoriasis: P = 0.0009; 134 
trios [58].
Table 1: Previously associated polymorphisms with other immune-mediated diseases and references. (Continued)Page 4 of 12
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metalloprotease (ADAM) 
domain 33, which is a 
member of the ADAM 
protein family. Has a role in 
cell-cell and cell-matrix 
interactions, including 
fertilization, muscle 
development, and 
neurogenesis. Reported as 
an asthma and bronchial 
hyper-responsiveness 
susceptibility locus.
ST+4 (rs44707)
V4 (rs2787094)
Q-1 (rs612709)
ST+7 (rs574174)
T+1 (rs2280089)
T2 (rs2280090)
0.48, 0.25, 0.24, 0.22, 0.08, 
0.07 UK & USA controls
Asthma and bronchial 
hyperresponsiveness: P = 
0.03 – 0.02; 130 cases and 
217 controls [35].
P = 0.04–0.0009 in 
ethnically diverse 
populations [59].
RUNX1 21q22.3 (861) The RUNX1 transcription 
factor is expressed mainly 
in hematopoietic cells and 
functions both to activate 
and to repress 
transcription through 
interactions with cofactors. 
This SNP alters a binding 
site for RUNX1 and has 
been associated with RA.
RUNX1 (rs2268277) 0.37 Japanese controls RA: P = 0.0013, OR= 1.28 
(95% CI = 1.10–1.48) 719 
cases and 441 controls 
[48].
MAF: minor allele frequency, SLE: systemic lupus erythematosus, RA: rheumatoid arthritis, GD: Graves' disease, HT: Hashimoto thyroiditis, T1D: 
type 1 diabetes, CD: Crohn disease, MS: multiple sclerosis, PA: Psoriatic arthritis, OR: odds ratio, 95% CI: 95% confidence intervals, N/A: not 
available
Table 1: Previously associated polymorphisms with other immune-mediated diseases and references. (Continued)Staden Package and loaded into T1Dbase. FCER1B was
also sequenced, as for CRP, in 96 T1D individuals for 2 kb
5' and 3 kb 3' of the gene and all exons, except exon 6,
were successfully sequenced.
SNPs were genotyped using either TaqMan MGB chemis-
try (Applied Biosystems), Invader Biplex assay (Third
Wave Technologies, Madison) [3] or PCR RFLP. The mic-
rosatellites were genotyped on an ABI3700 using fluores-
cent primers. All genotyping data were double scored to
minimize error.
Family studies of variants with a MAF less than 5% may be
compromised by apparent under transmission of alleles
resulting from undetected genotyping errors [27]. To eval-
uate potential genotyping errors we genotyped a large
selection of samples from three SNPs: SNP8 (rs2066844),
SNP12 (rs2066845), SNP13 (ss28514842), twice, using
two different methods, either TaqMan, Invader or PCR
RFLP. The concordance rate between the methods was
>99.2%.
Statistical analyses
All statistical analyses were performed within STATA [28]
making specific use of the Genassoc and htSNP2 packages
for association and tag SNP selection, available from [29].
All genotyping data of unaffected parents and controls
were assessed for, and found to be in Hardy-Weinberg
equilibrium (P > 0.05). Associations of the SNPs and mic-
rosatellites were tested by the Transmission/disequilib-
rium test in the families. Allelic and genotypic relative
risks were calculated using pseudo-controls and cases with
conditional logistic regression [30]. In order to minimise
any confounding due to variation in allele frequencies
across Great Britain [31], case-control data were stratified
by broad geographical region within the logistic regres-
sion model used to calculate ORs and test associations.
Both genotypic and allelic effects were allowed for by
modelling loci as three-level, 2 degrees of freedom (2 df),
categorical variables corresponding to a model assuming
no particular mode of inheritance and continuous (1 df)
variables equating to a multiplicative model. Where a dif-
ference was found, by a likelihood ratio test, between the
multiplicative model and a model assuming no particular
mode of inheritance, the 2 df P-value is reported. The tag
SNPs were analysed by use of a multivariate test statistic
[6,32].
Results
For CRP and FCER1B, we resequenced and followed a tag
selection approach, selecting tags that capture the varia-
tion of the remaining common SNPs (MAF ≥ 0.05) with a
minimum R2 of 0.8 [32]. Nineteen SNPs were identified in
CRP, five of which were novel (Additional File 2) [26] and
seven tag SNPs were selected and genotyped in set 1 fam-
ilies (multilocus P = 0.49). We also genotyped the tag
SNPs in the case-control collection (1,607 cases and 1,636
controls) and found no support for association (multilo-
cus P = 0.42), indicating that common variants of CRP are
unlikely to influence T1D susceptibility in a major way.
The CRP intronic microsatellite (GT)n polymorphism
(ss28514831) (Table 1 and Additional file 2) was alsoPage 5 of 12
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Table 2: Association analyses in type 1 diabetes families and case-control sample sets for immune-mediated disease associated polymorphisms.
Published SNP Set 1 families Cases and controls
MAF N parent-child 
trios (T/NT)
PTDT Allelic RR [95% CI] Genotype RR [95% CI] MAF N cases/
controls
P1df Allelic OR [95% CI] Genotype OR [95% CI]
FCRL3 A>G 
rs7528684
0.46 901 (641/571) 0.04 0.89 [0.80–1.00] A/A 1.00 [ref] A/G 0.88 [0.75–
1.04] G/G 0.79 [0.63–1.00]
0.45 1896/
2020
0.97 1.00 [0.91–1.10] A/A 1.00 [ref] A/G 1.02 [0.87–1.18] G/G 
0.99 [0.82–1.20]
CFH A>G 
rs1061170
0.38 823 (541/517) 0.46 0.96 [0.85–1.08] A/A 1.00 [ref] A/G 1.00 [0.85–
1.17] G/G 0.88 [0.68–1.14]
0.38 3149/
3485
0.87 0.99 [0.92–1.07] A/A 1.00 [ref] A/G 1.07 [0.96–1.19] G/G 
0.94 [0.81–1.10]
SLC9A3R1 G>A 
rs734232
0.45 965 (644/642) 0.96 1.00 [0.90–1.12] G/G 1.00 [ref] G/A 1.03 [0.88–
1.21] A/A 1.00 [0.80–1.25]
0.45 1578/
1736
0.34 1.05 [0.95–1.17] G/G 1.00 [ref] G/A 0.92 [0.78–1.10] A/A 
1.14 [0.92–1.41]
PADI4 C>T 
rs2240340
0.41 942 (610/655) 0.21 1.07 [0.96–1.20] T/T 1.00 [ref] C/T 1.07 [0.92–1.25] 
C/C 1.15 [0.92–1.44]
0.42 1573/
1732
0.87 1.01 [0.91–1.12] T/T 1.00 [ref] C/T 1.09 [0.92–1.29] C/C 
0.99 [0.80–1.23]
RUNX1 C>G 
rs2268277
0.34 896 (578/565) 0.70 1.02 [0.91–1.15] T/T 1.00 [ref] T/C 0.96 [0.83–1.11] 
C/C 1.12 [0.87–1.43]
0.36 1586/
1725
0.21 0.93 [0.84–1.04] T/T 1.00 [ref] T/C 0.90 [0.76–1.05] C/C 
0.90 [0.71–1.14]
SPINK5
+316 A>C 
ss28514851
0.04 178 (89/91) 0.88 0.98 [0.73–1.31] A/A 1.00 [ref] A/C 0.98 [0.73–
1.31] C/C 0.98 [0.10–9.55]
0.03 1540/
1678
0.40 0.88 [0.66–1.18] A/A 1.00 [ref] A/C 0.88 [0.65–1.19] C/C 
0.82 [0.14–4.71]
+1103 T>C 
rs2303064
0.48 915 (583/602) 0.58 0.97 [0.86–1.09] T/T 1.00 [ref] T/C 0.99 [0.84–1.17] 
C/C 0.94 [0.74–1.18]
0.47 1527/
1665
0.30 0.95 [0.85–1.05] T/T 1.00 [ref] T/C 0.96 [0.80–1.14] C/C 
0.89 [0.72–1.10]
+1156 G>A 
rs2303063
0.10 357 (196/213) 0.40 0.92 [0.76–1.12] G/G 1.00 [ref] G/A 0.93 [0.75–
1.15] A/A 0.81 [0.42–1.57]
0.11 1530/
1507
0.03 
2 df
0.87 [0.73–1.04] G/G 1.00 [ref] G/A 0.79 [0.64–0.96] A/A 
1.48 [0.72–3.03]
+1258 C>T 
rs2303067
0.48 947 (617/622) 0.89 0.99 [0.89–1.11] C/C 1.00 [ref] C/T 1.03 [0.87–
1.22] T/T 0.98 [0.79–1.23]
0.47 1534/
1641
0.36 0.95 [0.85–1.06] C/C 1.00 [ref] C/T 0.98 [0.82–1.17] T/T 
0.90 [0.73–1.12]
+2475 C>A 
rs2303070
0.07 317 (150/186) 0.05 0.81 [0.65–1.00] C/C 1.00 [ref] C/A 0.85 [0.68–
1.06] A/A 0.15 [0.02–1.13]
0.08 1479/
1513
0.06 
2 df
0.91 [0.73–1.12] C/C 1.00 [ref] C/A 0.82 [0.66–1.04] A/A 
2.51 [0.81–7.79]
+2915 A>G 
ss28514856
0.04 184 (92/105) 0.35 0.88 [0.66–1.16] A/A 1.00 [ref] A/G 0.87 [0.65–
1.17] G/G 0.82 [0.22–3.03]
0.03 1547/
1685
0.91 0.98 [0.72–1.33] A/A 1.00 [ref] A/G 0.98 [0.72–1.33] G/G 
-
MAF: Minor allele frequency, T: transmitted, NT: not transmitted, TDT: transmission/disequilibrium test P value, RR: relative risk, 95% CI: 95% confidence intervals, OR: odds ratio N: number.
BMC Medical Genetics 2006, 7:20 http://www.biomedcentral.com/1471-2350/7/20genotyped in set 1 and 2 families but showed no associa-
tion with T1D (P = 0.90).
On resequencing FCER1B, which is located in the putative
diabetes-susceptibility region IDDM4 [33], we identified
34 SNPs, 17 of which were novel, and selected five tag
SNPs (Additional File 3) [26]. We were unable to detect
the non-synonymous SNP in exon 7, Gly237Glu, in 96
DNA samples, that has previously been associated with
atopic asthma [16]. We initially genotyped the five tag
SNPs in set 1 families (multilocus P = 0.085), and then
followed this result up in set 2 families giving a combined
multilocus P = 0.070 (adjusted for two-stage design). In
1,600 cases and 1,636 controls we obtained P = 0.24, and
the combination of the multilocus family and case-con-
trol results indicated that variants of FCER1B are unlikely
to play a major role in T1D susceptibility (P = 0.23). The
FCER1B intronic microsatellite polymorphism
(ss28514807) also showed no evidence of association
with T1D in set 1 and 2 families (P = 0.65).
Five SNPs from FCRL3, CFH, SLC9A3R1, PADI4, RUNX1
and six SNPs from SPINK5 were genotyped in set 1 fami-
lies and a minimum of 1,500 cases and 1,500 controls
(Table 2). All except FCRL3 (TDT P = 0.04) and one locus
in SPINK5 (P = 0.03), showed a P value of > 0.05. How-
ever, we did not obtain any further evidence of association
of FCRL3 in 1,896 cases and 2,020 controls (Table 2).
IL1RN, IL1RA, IGR2198 and the CARD15 SNPs 8, 12 and
13 were genotyped in sets 1 and 2 families, and all showed
P > 0.10 (Table 3). The two SLC22A4 SNPs and the single
LAG3 SNP were genotyped in a minimum of 3,290 cases
and 3,549 controls and showed no evidence of associa-
tion with T1D (Table 3).
As a potential atopy/asthma susceptibility locus, ADAM33
was considered as a candidate gene for T1D because
atopic illness and T1D have been inversely associated
[34]. No functional candidate SNPs in ADAM33 have
been identified, but it is plausible that the SNPs in introns
or the 3' region are located in regulatory sequences and
thus may affect transcriptional efficiency or transcript sta-
bility [35]. We genotyped six SNPs that showed a P ≤ 0.03
in asthma case-control data [35] in set 1 families (Tables
1 and 4). One SNP, ADAM33 V4 (rs2787094), showed P
= 0.0004 (RR = 0.78, 95% CI = 0.67–0.89) initially in 754
families, and P = 4.4 × 10-6 (RR = 0.77, 95% CI = 0.69–
0.86) when genotyped in the additional set 2 families.
However, we did not obtain additional support for associ-
ation in 4,326 cases and 4,610 controls (P = 0.57) (Table
4).
Finally, we genotyped the NFKB1 dinucleotide repeat
(CA) microsatellite polymorphism, which has been asso-
ciated with T1D [36], albeit inconsistently [37] (Table 1).
In our set 1 families, we failed to find any evidence for an
association with T1D (P = 0.68).
Discussion
Co-localization and overlapping of genetic loci in autoim-
mune diseases suggests that in some cases, common bio-
logical pathways may be involved in the aetiology of T1D
and other clinically distinct immune-mediated diseases.
In this study we examined 16 genes implicated in autoim-
mune and other immune-mediated diseases and report
that none of the variants tested, consistently showed P val-
ues of less than 0.05 in association tests with T1D. Our
data indicate that, although common immune-mediated
disease loci are present in the genome, there are disease
genes that are distinct to certain diseases. Indeed, the
known T1D susceptibility loci follow this observation:
while both CTLA4 and PTPN22 loci are associated with
several autoimmune diseases [3,38], the insulin VNTR
locus is likely to be T1D-specific rather than a general
autoimmune locus [7].
Conclusion
The possibility remains that some of the investigated
genes and variants are associated with T1D, albeit with
weak genetic effects, such as with ORs of less than 1.3, for
which the sample size employed in our study does not
provide sufficient statistical power. Even a case-control
sample of 8,000 cases and 8,000 controls would only have
48% statistical power at a type 1 error rate α of 0.001 for
a disease variant with a MAF of 0.10 and OR of 1.15. As
genotyping costs decrease, it will be necessary to test the
variants in larger sample sets than reported here, because
the identification of genetic effects with ORs in the 1.15–
1.25 range can be instrumental in the understanding of
the disease process of T1D [3]. For example, we note that
an observed genetic effect of OR 1.15, such as that exerted
by the T1D susceptibility locus CTLA4, does not reflect the
importance of the biological effect contributed by the
locus through the protein(s) it encodes and the pathways
it regulates [3].
Lack of association with variants tested here may also be
partly due to false positive results obtained in the reported
primary disease association studies. As shown in Table 1,
these generally employed small sample sets, which is a
common explanation in the reporting of P values that can-
not be replicated in independent studies using larger sam-
ple sizes [39-42]. Nevertheless, for ORs >1.5 our present
study had good statistical power even for alleles at 0.01
frequency.
Abbreviations
T1D-type 1 diabetes, SNPs-single nucleotide polymor-
phisms, MAF-minor allele frequency, OR-odds ratio, RR-
relative risk, RA-rheumatoid arthritis, SLE-systemic lupusPage 7 of 12
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Table 3: Association analyses in type 1 diabetes families and case-control sample sets for rheumatoid arthritis, inflammatory bowl disease and multiple sclerosis associated 
polymorphisms.
Published SNP Set 1 and 2 families Cases and controls
MAF N parent-child trios 
(T/NT)
PTDT Allelic RR [95% CI] Genotype RR [95% CI] MAF N Cases/
controls
P1df Allelic OR [95%CI] Genotype OR [95%CI]
IL1RN +2017 T>C 
rs2419598
0.28 1418 (916/865) 0.23 1.06 [0.96–1.16] T/T 1.00 [ref] T/C 1.12 [0.99–
1.25] C/C 1.03 [0.83–1.28]
n/a n/a n/a n/a n/a
IL1RA -889 C>T 
rs1800587
0.30 1431 (925/913) 0.78 1.01 [0.92–1.11] C/C 1.00 [ref] C/T 1.02 [0.91–
1.15] T/T 1.02 [0.83–1.25]
n/a n/a n/a n/a n/a
CARD15
SNP8 +2023C>T 
rs2066844
0.03 252 (123/143) 0.22 0.86 [0.68–1.09] C/C 1.00 [ref] C/T 0.90 [0.70–
1.15] T/T 0.22 [0.03–1.66]
n/a n/a n/a n/a n/a
SNP12 +3641G>C 
rs2066845
0.01 127 (57/72) 0.19 0.79 [0.56–1.12] G/G 1.00 [ref] G/C 0.81 [0.57–
1.14] C/C -
n/a n/a n/a n/a n/a
SNP13 +2936insC 
ss28514842
0.01 143 (73/72) 0.93 1.01 [0.73–1.40] 1/1 1.00 [ref] 1/2 1.00 [0.72–
1.38] 2/2 2.99 [0.19–48.22]
n/a n/a n/a n/a n/a
IGR2198 G>C 
rs11739135
0.40 1511 (988/1008) 0.65 0.98 [0.90–1.07] G/G 1.00 [ref] G/C 0.95 [0.84–
1.07] C/C 0.98 [0.82–1.17]
n/a n/a n/a n/a n/a
SLC22A4 G>A 
rs3792876
n/a n/a n/a n/a n/a 0.08 3303/3558 0.93 0.99 [0.87–1.14] C/C 1.0 [ref] C/T 1.01 [0.87–
1.16] T/T 0.83 [0.40–1.70]
SLC22A4 C>T 
rs2073838
n/a n/a n/a n/a n/a 0.08 3290/3549 0.79 0.98 [0.86–1.12] G/G 1.00 [ref] G/A 1.00 [0.87–
1.15] A/A 0.74 [0.36–1.52]
LAG3 G>A 
rs870849
n/a n/a n/a n/a n/a 0.36 3860/4297 0.90 1.00 [0.93–1.06] G/G 1.00 [ref] G/A 1.00 [0.91–
1.10] A/A 0.99 [0.86–1.14]
MAF: Minor allele frequency, T: transmitted, NT: not transmitted, TDT: transmission/disequilibrium test P value, RR: relative risk, 95% CI: 95% confidence intervals, OR: odds ratio, N: number, 
n/a: not attempted
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Table 4: Association analyses in type 1 diabetes families and case-control sample sets for ADAM33 SNPs
Published SNP Set 1 families Cases and controls
MAF N parent-child 
trios (T/NT)
PTDT Allelic RR [95% CI] Genotype RR [95% CI] MAF N cases/
controls
P1df Allelic OR [95%CI] Genotype OR [95%CI]
ST+4 rs44707 0.39 703 (421/443) 0.02* 0.95 [0.83–1.09] C/C 1.00 [ref] A/C 0.80 
[0.67–0.96] A/A 0.99 [0.76–
1.30]
n/a n/a n/a n/a n/a
**V4 rs2787094 0.23 653 (350/451) 0.0004 0.78 [0.67–0.89] G/G 1.00 [ref] G/C 0.78 
[0.67–0.92] C/C 0.59 [0.41–
0.85]
0.22 4326/4610 0.57 1.02 [0.95–1.10] G/G 1.00 [ref] G/C 1.04 
[0.95–1.14] C/C 0.99 
[0.81–1.22]
Q-1 rs612709 0.14 402 (219/247) 0.02* 0.89 [0.74–1.06] G/G 1.00 [ref] G/A 0.99 
[0.81–1.21] A/A 0.42 [0.22–
0.83]
n/a n/a n/a n/a n/a
ST+7 rs574174 0.20 669 (392/393) 0.97 1.00 [0.87–1.15] T/T 1.00 [ref] T/C 1.02 
[0.87–1.20] C/C 0.92 [0.63–
1.34]
n/a n/a n/a n/a n/a
T+1 rs2280089 0.13 512 (274/304) 0.21 0.90 [0.77–1.06] G/G 1.00 [ref] C/G 0.90 
[0.75–1.07] C/C 0.83 [0.49–
1.43]
n/a n/a n/a n/a n/a
T2 rs2280090 0.13 520 (277/314) 0.13 0.88 [0.75–1.04] T/T 1.00 [ref] T/C 0.88 
[0.73–1.05] C/C 0.81 [0.47–
1.39]
n/a n/a n/a n/a n/a
MAF: minor allele frequency. T: transmitted. NT: not transmitted. TDT: transmission/disequilibrium test. P value. RR: relative risk. 95% CI: 95% confidence intervals. OR: odd ratios. N: number. 
n/a: not attempted.
* Two degree of freedom GTRR (genotype relative risk) P value is reported as its significantly different to the TDT P value.
** In set 1 and 2 families (1075(571/737) parent-child trios) for ADAM33 V4, PTDT = 4.43 × 10-6, with allelic RR = 0.77 [0.69–0.86] and genotype relative risks: G/G 1.00 [ref], G/C 0.80 [0.70–0.91], 
C/C 0.54 [0.40–0.73].
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tis, MS-multiple sclerosis.
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